The new, state-of-the-art manufacturing facility, operated by Heritage Pharma Labs Inc. (“Heritage Pharma Labs”), consists of dispensaries/pharmacies and multiple manufacturing suites to hold fixed and portable equipment to perform pharmaceutical operations like mixing, granulation, drying, milling/sieving, compaction, extrusion/spheronization, blending, compression, coating, encapsulation and packaging
Oliver Healthcare Packaging Increases Global Manufacturing Footprint to Strengthen Local Customer Support and Service in Asia Pharmaceutical and Medical Device Markets. In addition to product manufacturing, the new ISO 7 cleanroom facility will include a testing lab & technical service center, a microbiological lab, and warehouse & distribution facilities. All equipment has been built and validated to meet or exceed ISO 13485 quality specifications.
AbbVie’s Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis. Atopic dermatitis, a chronic inflammatory skin disease, is characterized by skin erosion, oozing and crusting, redness, intense itching (pruritus) and dry skin.12 Symptoms can appear as a rash on the skin, or the skin may become thickened and leathery.
Researchers at ITMO University developed a new approach for obtaining non-toxic magnetic photonic crystals, expanding their applications from mainly photonics to biomedicine. Nanospheres made with the new method may be used for designing drugs to fight thrombosis and cancer.
Capsugel, now a Lonza company, a global leader in delivering high-quality, innovative dosage forms and solutions, today announced expanded clinical trial capabilities, as well as increased development and manufacturing capabilities for specialized drug products utilizing liquid-filled hard capsule (LFHC) technology, at its Edinburgh facility in Scotland.
Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Advanced Accelerator Applications (NASDAQ:AAAP) is a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines including Lutathera®
Batavia Biosciences announces the expansion of its viral vector process development facilities in the USA and its GMP clean room facilities in the Netherlands to accommodate the increasing market demand.
Equashield will invest an estimated $30 million to build the new plant to meet the growing market demand for manual and automated hazardous drug compounding devices.
